Search Results

You are looking at 121 - 130 of 383 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022

Featured Updates to the NCCN Guidelines

Peter L. Greenberg, Richard M. Stone, Aref Al-Kali, John M. Bennett, Uma Borate, Andrew M. Brunner, Wanxing Chai-Ho, Peter Curtin, Carlos M. de Castro, H. Joachim Deeg, Amy E. DeZern, Shira Dinner, Charles Foucar, Karin Gaensler, Guillermo Garcia-Manero, Elizabeth A. Griffiths, David Head, Brian A. Jonas, Sioban Keel, Yazan Madanat, Lori J. Maness, James Mangan, Shannon McCurdy, Christine McMahon, Bhumika Patel, Vishnu V. Reddy, David A. Sallman, Rory Shallis, Paul J. Shami, Swapna Thota, Asya Nina Varshavsky-Yanovsky, Peter Westervelt, Elizabeth Hollinger, Dorothy A. Shead, and Cindy Hochstetler

discussed the addition of eltrombopag to immunosuppressive therapy (IST) for patients with lower-risk MDS, and voted to modify a footnote (see MDS-3 , page 108). In the setting of clinically relevant thrombocytopenia or neutropenia, IST is recommended as an

Full access

New Approaches to Endocrine Therapy for Breast Cancer

William J. Gradishar

monitor WBC counts in patients receiving palbociclib and ribociclib, but those who develop neutropenia “generally don't feel the effects” and febrile neutropenia is uncommon, he indicated. “As we move forward,” he added, clinicians can expect “the coming

Full access

Chronic Lymphocytic Leukemia: Individualizing Treatment Approach

Andrew D. Zelenetz

(PFS) and complete response (CR) rate. However, BR was associated with lower rates of neutropenia and severe infections in elderly patients, suggesting that it may be considered as an alternative first-line regimen in fit, elderly patients. Long

Full access

Guidelines for NHL: Updates to the Management of Diffuse Large B-Cell Lymphoma and New Guidelines for Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders and T-Cell Large Granular Lymphocytic Leukemia

Andrew D. Zelenetz

indicated. Indications for therapy for TLGLL include severe neutropenia (absolute neutrophil count <0.5 x 10 9 /L), moderate neutropenia with recurrent infections, symptomatic or transfusion-dependent anemia, autoimmune disorders associated with TLGLL, and B

Full access

Supportive Care in Head and Neck Cancers: Multidisciplinary Management

Presented by: Jimmy J. Caudell, David G. Pfister, and Randal S. Weber

febrile neutropenia. He received empiric antibiotics and antifungal medications, the neutropenia and fever resolved, and he was discharged. He did not require a nasal gastric tube or a PEG tube during treatment, and he went on to receive adjuvant

Full access

Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas

Presented by: Ann S. LaCasce and Ariela Noy

<.001). 2 The addition of lenalidomide to rituximab was also associated with a trend in improvement in overall survival. “As expected, the combination regimen had higher rates of neutropenia, but infection rates were similar,” she said. “There was also

Full access

Treatment Updates in Acute Myeloid Leukemia

Presented by: Alexander E. Perl

- or poor-risk cytogenetics. 6 Every drug has adverse effects, and oral azacitidine carries the risk of significant gastrointestinal toxicity, for which preemptive antiemetics are recommended. Neutropenia is common, but can be managed with dose

Full access

Management of Toxicities of BTK Inhibitors in B-Cell Malignancies

Presented by: Muhammad Saad Hamid and Kirollos S. Hanna

cautioned. Dr. Hanna noted that hematologic adverse effects can be profound with drugs such as ibrutinib and zanubrutinib, with up to 25% to 30% of patients experiencing grade 3/4 neutropenia. When using these drugs, clinicians should consider infection

Full access

Treatment of Non–Small Cell Lung Cancer in the Older Patient

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III, and Arti Hurria

concurrent chemotherapy and radiation. They found that although acute toxicities (esophagitis and neutropenia) were higher in older patients, no differences were seen in long-term toxicity or overall survival based on age. In a similar analysis, Schild et al

Full access

Predictive Molecular Markers: Has the Time Come for Routine Use in Lung Cancer?

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock, and David R. Gandara

. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis . Cancer Res 2000 ; 60 : 6921 – 6926 . 26 Innocenti F Undevia SD Iyer L . UGT1A1*28 polymorphism is a predictor of neutropenia in irinotecan